Letrohope 2.5mg Tablet 5s

Letrohope 2 5mg Tablet 5s is a medication often prescribed for hormone receptor-positive (HR+) breast cancer in postmenopausal women. It suppresses the enzyme that converts androgens into oestrogens in peripheral tissues such as fat, muscle, and the breast. By blocking this conversion, Letrohope 2 5mg Tablet 5s lowers circulating and tissue oestrogen by 75–95%, depriving hormone stimulus to oestrogen-dependent breast cancer cells. Letrohope 2 5mg Tablet 5s is also used for ovulation induction in polycystic ovary syndrome (PCOS) and for other infertility indications under specialist supervision.

Letrozole is a third-generation, non-steroidal, selective aromatase inhibitor (AI). In breast cancer, Letrohope 2 5mg Tablet 5s is used as adjuvant therapy after surgery in postmenopausal HR+ early-stage disease, as extended adjuvant therapy after 5 years of tamoxifen, and as first- or second-line treatment in locally advanced or metastatic HR+ disease.

Compared with tamoxifen (another hormone therapy to treat the same kind of breast cancer) in large clinical trials, letrozole has shown superior disease-free survival in postmenopausal HR+ early breast cancer.

Research shows that, in PCOS-related anovulatory (no ovulation) infertility, letrozole is widely used as a first-line agent over clomiphene citrate, based on higher ovulation and live-birth rates, lower multiple-pregnancy rates, and a more favourable endometrial environment.

• Used either as initial or additional adjuvant therapy to treat hormone receptor-positive (HR+) breast cancer in postmenopausal women after 5 years of tamoxifen.

• First-line treatment of HR+ or receptor-unknown advanced or metastatic breast cancer in postmenopausal women.

• Second-line treatment of advanced breast cancer in postmenopausal women with progression after anti-estrogen therapy.

• Used as an adjunct in IVF cycles, especially in poor responders and in women with oestrogen-sensitive cancers under medical supervision only.

• Used to reduce local oestrogen exposure in endometriosis-related pain and uterine fibroids under medical supervision only.

• Suppresses 75 to 95% of serum oestrogen, including oestradiol, oestrone, and oestrone sulphate.

• Established superiority to tamoxifen in disease-free survival in postmenopausal HR+ early breast cancer.

• Lowers the risk of contralateral breast cancer and distant metastases (spread) when used alongside.

• Does not cause endometrial stimulation or thromboembolism (clot blocking the flow of blood), which is often seen with tamoxifen.

• Targets aromatase only and does not affect corticosteroid and aldosterone production.

• In PCOS, it produces monofollicular ovulation more often than clomiphene, with higher live-birth rates and fewer multiple pregnancies.

• Convenient once-daily oral dosing. Generally well tolerated.

Common:

• Hot flushes, night sweats
• Arthralgia (joint pain), myalgia (muscle pain)
• Fatigue, headache
• Thinning & shedding of hair
• Nausea, weight gain

Uncommon:

• Vaginal dryness, itching, dyspareunia (consistent genital pain)
• Mood changes, depression, insomnia (sleeplessness)
• Dizziness
• Mild increase in cholesterol, triglycerides, or liver enzymes
• Peripheral oedema (swelling due to fluid buildup)

Serious side effects requiring immediate attention:

• Bone loss, osteopenia, osteoporosis, and increased fracture risk with long-term use

• Cardiovascular issues such as ischaemic heart disease, chest pain, and hypertension (high blood pressure)

• Severe hepatic dysfunction (rare), which manifests as jaundice, unexplained abdominal pain

• Thromboembolism (rare)

• Severe allergic reactions, angioedema, or toxic epidermal necrolysis (very rare)

• Foetal harm if taken during pregnancy (for breast cancer indication)

Take the medicine as recommended by your doctor. For breast cancer, your doctor may recommend one tablet orally once daily, with or without food, at the same time each day. The duration for the medication can vary: 5 years as an adjuvant, up to 5 additional years as an extended adjuvant, and until progression in advanced disease. For ovulation induction in PCOS, a fertility specialist may recommend taking medication once daily for 5 days starting on day 2 or 3 of the cycle, with daily escalation in non-responders. Swallow whole with water. If you vomit shortly after a dose, do not take an extra dose. Do not discontinue without consulting your oncologist or fertility specialist. Bone density, lipid profile, and liver function should be monitored frequently in long-term users.

In postmenopausal women, ovaries no longer produce significant oestrogen. Instead, the main source is peripheral conversion of adrenal and ovarian androgens into oestrogens by aromatase (CYP19), particularly in adipose tissue, muscle, liver, and breast tissue (including breast cancer cells). Many breast cancers are oestrogen-dependent as their cells carry oestrogen receptors (ER+), and require oestrogen for multiplication and survival. Lowering oestrogen starves these cancers of their key growth signal.

Letrohope 2 5mg Tablet 5s is a non-steroidal, competitive, reversible inhibitor of aromatase. Its triazole ring binds tightly to the haem iron of the cytochrome P450 subunit of aromatase, blocking the active site so androgens cannot be converted to oestrogens. This reduces oestradiol, oestrone, and oestrone sulphate by 75–95% within 2–3 days, suppressing both peripheral and intratumoural (within the tumour) oestrogen. Because Letrohope 2 5mg Tablet 5s acts specifically on aromatase, it does not affect corticosteroid, aldosterone, or thyroid synthesis.

In premenopausal women with PCOS, the mechanism differs. By transiently reducing oestrogen, letrozole removes negative feedback on the hypothalamus, triggering a compensatory rise in follicle-stimulating hormone (FSH) from the pituitary, which stimulates follicular development and ovulation. Unlike clomiphene (another medicine used to treat fertility), Letrohope 2 5mg Tablet 5s does not block oestrogen receptors. This results in better endometrial thickness and cervical mucus as the endometrial and cervical oestrogen receptors remain functional. Its short half-life (approximately 2 days) means it is cleared before implantation, reducing theoretical foetal exposure.

• Alcohol (MODERATE): Worsens hot flushes, dizziness, fatigue, and increases the burden on the liver.

• Soy and phytoestrogen-rich foods (CAUTION): Very high doses should not be consumed in HR+ breast cancer. Usual dietary amounts are safe.

• Calcium and Vitamin D-rich foods (BENEFICIAL): Support bone health during long-term therapy.

Tamoxifen

SEVERE

Reduces plasma letrozole by approx. 35 to 40%. Use sequentially, not concurrently.

Oestrogen-containing medications (HRT, OCPs, vaginal oestrogen)

SEVERE

Directly oppose the pharmacological effect. Avoid all systemic oestrogens during breast cancer therapy.

Strong CYP3A4/CYP2A6 inducers (rifampicin, phenytoin, carbamazepine, St John's Wort)

MODERATE

Accelerate metabolism and reduce efficacy.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin)

MODERATE

May increase exposure. Monitor for adverse effects.

Warfarin and anticoagulants

CAUTION

Additional bleeding risk in some patients. Monitor PT/INR frequently.

Bisphosphonates, denosumab

BENEFICIAL

Often co-prescribed to mitigate induced bone loss.

NSAIDs (regular use)

CAUTION

May worsen fluid retention and joint symptoms.

• Premenopausal status (breast cancer): Ineffective without ovarian suppression (GnRH agonists (suppress the release of sex hormones) or oophorectomy(removal of one or both ovaries).

• Osteoporosis or high fracture risk: Accelerates bone loss.

• Cardiovascular risk: Increased risk of cardiovascular events as compared to tamoxifen. Get regular checkups done.

• Severe hepatic impairment: Low clearance from liver.

• Hyperlipidaemia: May worsen cholesterol and triglyceride levels.

• Pregnancy: In fertility treatment, used only before conception under specialist supervision.

• Endometrial / ovarian pathology: Baseline pelvic ultrasound advised before ovulation induction.

There are limited reports of Letrohope 2 5mg Tablet 5s overdose. Symptoms may include dizziness, fatigue, nausea, vomiting, and flushing. There is no specific antidote. Management may include close monitoring of vital signs and symptomatic treatment. Seek immediate emergency medical attention in suspected overdose.

Take a missed dose as soon as you remember on the same day, as long as it is several hours before the next dose. If close to the next dose, skip it and resume the regular schedule. Never double-dose. For ovulation induction, strictly adhere to the 5-day course. If a dose is missed, contact your fertility specialist immediately, as the cycle may need to be re-planned.